Market Research Report
Venous Thromboembolism Treatment Market Size By Device, By Application, By End-use, Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2021 - 2027
|Published by||Global Market Insights Inc.||Product code||1002920|
|Published||Content info||120 Pages
Delivery time: 2-3 business days
|Venous Thromboembolism Treatment Market Size By Device, By Application, By End-use, Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2021 - 2027|
|Published: April 23, 2021||Content info: 120 Pages||
Venous Thromboembolism Treatment Market Size By Device (Compression System, Thrombectomy Systems, IVC Filters, Stockings), By Application (Deep Vein Thrombosis, Pulmonary Embolism), By End-use (Hospitals, Catheterization Laboratories), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2021 - 2027.
The venous thromboembolism treatment is anticipated to observe commendable growth by 2027 owing to availability of sophisticated cath labs, rising geriatric population, increasing demand for better medication for patients, and increasing prevalence of cancer and obesity.
The term venous thromboembolism refers to blood clots or a blood clot in the veins. It is a serious and underdiagnosed, still preventable medical condition which could cause death or disability. VTE is in fact the third known vascular diagnosis after stroke and heart attack, which is known to affect nearly 300,000 to 600,000 American citizens each year.
The most commonly known triggers for VTE are hospitalization, immobilization, surgery, and cancer. Thrombolytic and anticoagulant therapy options are mostly available for the treatment of VTE.
The venous thromboembolism treatment market is segmented in terms of device, application, end-use, and regional landscape.
With respect to device, the market for venous thromboembolism treatment is classified into stockings, IVC filters, thrombectomy systems, compression system, and others. The stockings segment is anticipated to showcase a CAGR of over 7.8% through the forecast period. This growth is ascribed to the rising product adoption due to reduced swelling and pain coupled with improved blood flow.
Based on application, the market is divided into pulmonary embolism and deep vein thrombosis. In 2020, the deep vein thrombosis segment accounted for more than $530 million and is anticipated to witness substantial growth over the coming years. Rising geriatric population, increasing prevalence of cancer and obesity are some of the primary risk factors that will drive the segmental growth.
DVT is basically a clot in a deep vein, generally in the leg. At times, deep vein thrombosis affects the arm or other veins. It usually forms in the legs when something changes or slows the flow of blood. To be specific, in women, the use of hormones such as estrogen or oral contraceptives for menopause symptoms or pregnancy could also play a role.
In terms of end-use, the overall venous thromboembolism treatment market is bifurcated in terms of catheterization laboratories, hospitals, and others. The catheterization laboratories segment is likely to expand at a CAGR of 9.7% throughout the review period. The growth is majorly attributed to the high patient volume in cath labs and increasing demand for better medication for patients.
From a regional frame of reference, in North America, the U.S. accounted for more than $380 million in 2020 and will continue to exhibit similar growth patterns over the coming years. High presence of prominent players such as AngioDynamics and Boston Scientific will augment the market growth. Subsequently, the growing adoption of advanced products and availability of sophisticated cath labs across the region will contribute towards regional market growth.